Stock Ratings / Health Care / BGMS / financials

GELS (59) LGVN (32) PCSA (48) SCNX (42) ⌘ Pro Terminal →

Bio Green Med Solution Inc. (BGMS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.83 -9.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.81

Bio Green Med Solution Inc. (BGMS) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $5.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.81 (-1.95%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BGMS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY BGMS SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.85+7.1% Next Q

Q2 (-2Q)

Grade D$0.91+5.5% Next Q

Q3 (-1Q)

Grade D$0.96-13.5% Next Q

Current

Grade D-$0.83-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BGMS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BGMS currently carries a cautious 40/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.90) and Max Pain ($0.87) forces dealer call-delta covering toward $2.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BGMS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BGMS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How BGMS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $43.0K

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.2%	-$3.0M	-$4.8M	-45%
FY 2024	$43.0K	52%	-80%	-$11.2M	-$8.0M	-45%
FY 2023	$4.00B	52%	-0.6%	$22.6M	-$16.1M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BGMS)

✓Walkthrough of BGMS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BGMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.43%📐 HORIZONTAL RANGE

2026-10-30O $0.90H $0.92L $0.83C $0.83VOL 11.5K

RES: $1.17SUP: $0.58SMA50: $0.90SMA200: $0.97

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BGMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BGMS Butterfly Map → + Track BGMS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BGMS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BGMS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BGMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BGMS)

Health Care Rank #655 of 1016 ⚔️ GELS vs BGMS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BGMS vs. GELS, LGVN, PCSA, SCNX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bio Green Med Solution Inc. (BGMS) ranks #655 by composite RQD confidence (40/100, grade D-) and #937 by equity capitalization ($5.5M). Within this direct 5-issuer industry benchmark cohort, BGMS leads on earnings valuation at N/A trailing P/E, while BGMS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with BGMS at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BGMS ACTIVE Bio Green Med Solution Inc.	D-	40/100	—	—	-35.0%	-9.79%	$5.5M	Benchmark Subject
GELS Gelteq Limited	C-	59/100	—	—	—	+5.11%	$5.4M	/gels-vs-bgms →
LGVN Longeveron Inc. (Class A)	E	32/100	—	67.0%	-35.0%	-1.68%	$5.6M	/lgvn-vs-bgms →
PCSA Processa Pharmaceuticals Inc.	D	48/100	—	—	-35.0%	+2.16%	$5.3M	/pcsa-vs-bgms →
SCNX Scienture Holdings Inc.	D-	42/100	—	76.8%	-35.0%	+2.65%	$5.7M	/scnx-vs-bgms →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001130166

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bio Green Med Solution Inc. (BGMS) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $43.0K ) , GAAP net income of -$3.0M, operating cash flow of -$4.8M, and free cash flow of -$4.8M (+40.3% YoY). On the balance sheet, BGMS closed FY2025 with $8.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$3.0M	-$4.8M	-$4.8M	$8.2M	—
FY2024 (FY)	2024-12-31	$43.0K	-$11.2M	-$8.0M	-$8.0M	$4.1M	—
FY2023 (FY)	2023-12-31	$0	$22.6M	-$16.1M	-$16.1M	—	—

3. BGMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BGMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Bio Green Med Solution Inc. (NASDAQ: BGMS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.83 (-9.79% 1D, market cap $5.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BGMS ranks #655 in composite RQD confidence.

How does BGMS compare to GELS and LGVN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BGMS carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GELS (Gelteq Limited) holds a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $5.4M) and LGVN (Longeveron Inc. (Class A)) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $5.6M). Among the 5-stock peer group, BGMS leads on earnings multiple (N/A) while BGMS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BGMS?

Per BGMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001130166), Bio Green Med Solution Inc. generated $0 in revenue (-100.0% YoY), -$3.0M in net income, and -$4.8M in free cash flow against $8.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BGMS trading relative to its 50-day, 200-day, and 52-week technical levels?

BGMS last traded at $0.83 (-9.79% on volume of 20,250 shares), positioning the stock -7.78% below its 50-day simple moving average ($0.90) and -14.43% below its 200-day simple moving average ($0.97). Across its 52-week range of $0.57 to $2.80, BGMS sits at the 11.7% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.93).

BGMS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Bio Green Med Solution Inc. (BGMS)?

In FY 2025 (10-K), BGMS converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: BGMS RQD Cockpit BGMS 12M Forecast BGMS Earnings & Move BGMS Dividends & DRIP BGMS Insiders & 13F BGMS Whale Options BGMS Profit Sankey BGMS News & Why